sparsomycin

Sparsomycin is a cytotoxic antitumor antibiotic originally isolated from the bacterium Streptomyces sparsogenes. It acts as a potent inhibitor of protein synthesis by binding to the large (50S) ribosomal subunit and blocking peptide bond formation through inhibition of peptidyl transferase activity. Sparsomycin inhibits protein synthesis in both prokaryotic (70S) and eukaryotic (80S) ribosomes. While it demonstrated broad-spectrum in vitro activity against various tumor cell lines and was investigated for anticancer use, its clinical development was halted due to significant toxicity—most notably retinopathy observed during early human trials. Today, it is primarily used as a research tool to study mechanisms of translation and ribosome function[1][2][3][4][5][7].

Other names

sparsomycinesparsomicinasparsomycinesparsomycinum